Business
Notice of 2025 Full Year Results and IMC
IXICO plc will release its Full Year Results for the year ending 30 September 2025 on Tuesday, 09 December 2025, and will host a live investor presentation on the Investor Meet Company platform at 16:30 GMT on the same day. Existing and potential shareholders can submit questions prior to the event by 09:00 GMT on 08 December 2025 or during the presentation. A recording of the results presentation will be made available on the company's website. Disclaimer*
About this update from Ixico Plc
[{"type":"text","content":"\n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nNotice of 2025 Full Year Results and Investor Presentation\n \n \n27 November 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, confirms it will issue its Full Year Results for the year to 30 September 2025 on Tuesday 09 December 2025.\n \nBram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to the Full Year Results and the Company's progress and ongoing strategy via:\n \nThe Investor Meet Company platform on 09 December 2025 at 16:30 GMT.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 GMT on 08 December 2025, or at any time during the live presentation.\n \nInvestors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:\n \nhttps://www.investormeetcompany.com/ixico-plc/register-investor\n \nInvestors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.\n \nA recording of the results presentation will be made available on the Group's website.\n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \nFor further information please contact:\n\n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7499\n\n\n\n\nGrant Nash, Chief Financial Officer\nJames Chandler, Chief Business Officer\n\n\n\n\n\n\n\n \nCavendish Capital Markets Limited\n(Nominated Adviser and Sole Broker)\n\n\n \n+44 (0) 20 7220 0500\n\n\n\n\nGiles Balleny (Corporate Finance)\nNigel Birks (Healthcare Specialist Sales)\nHarriet Ward (Corporate Broking)\nMichael F Johnson (Sales)\n\n\n\n\n\n\n\n \nAbout IXICO www.IXICO.com\nIXICO is a global leader in neuroscience imaging and biomarker analytics, using i...